# EDGAR Filing Document

**Accession Number:** 0001351172
**File Stem:** 0000950170-23-001698
**Filing Date:** 2023-2
**Character Count:** 6326
**Document Hash:** 69d56f28ed78fe4b1ff1a3c3ac1b9916
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-001698.hdr.sgml**: 20230202

**ACCESSION NUMBER**: 0000950170-23-001698

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 6

**CONFORMED PERIOD OF REPORT**: 20230202

**FILED AS OF DATE**: 20230202

**DATE AS OF CHANGE**: 20230202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Liminal BioSciences Inc.
- **CENTRAL INDEX KEY:** 0001351172
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39131
- **FILM NUMBER:** 23580810

**BUSINESS ADDRESS:**
- **STREET 1:** 231 DUNDAS STREET EAST
- **CITY:** BELLEVILLE
- **STATE:** A6
- **ZIP:** K8N 1E2
- **BUSINESS PHONE:** 450-781-0115

**MAIL ADDRESS:**
- **STREET 1:** 440 ARMAND-FRAPPIER BLVD.
- **STREET 2:** SUITE 300
- **CITY:** LAVAL
- **STATE:** A8
- **ZIP:** H7V 4B4

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ProMetic Life Sciences Inc
- **DATE OF NAME CHANGE:** 20060126

**UNITED STATES SECURITIES**

**AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the Month of February 2023**

**Commission File Number: 001-39131**

**LIMINAL BIOSCIENCES INC.**

**(Translation of registrant's name into English)**

------

**440 Armand-Frappier Boulevard, Suite 300**

**Laval, Québec**

**H7V 4B4**

**(Address of principal executive office)**

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: ☒ Form 20-F ☐ Form 40-F

------

**<u>INCORPORATION BY REFERENCE</u>**

This Report on Form 6-K (the "Report") and Exhibits 99.1 and 99.2 to this Report are hereby expressly incorporated by reference into the registrant's registration statements on Form F-3 (File nos. 333-251055, 333-245703 and 333-251065) filed with the Securities and Exchange Commission on December 1, 2020, December 2, 2020 and December 2, 2020, respectively, and the registration statement on Form S-8 (File no. 333-235692) filed with the Securities and Exchange Commission on December 23, 2019.

**<u>EXHIBIT LIST</u>**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [<u>Certificate of Amendment of Liminal BioSciences Inc. dated January 25, 2023</u>](lmnl-ex99_1.htm) |
| 99.2 | [<u>Material change report dated February 2, 2023</u>](lmnl-ex99_2.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Liminal BioSciences Inc.** | **Liminal BioSciences Inc.** | **Liminal BioSciences Inc.** |
| Date: February 2, 2023 | By: | /s/ Bruce Pritchard | /s/ Bruce Pritchard |
|  |  | Name | Bruce Pritchard |
|  |  | Title: | Chief Executive Officer |

---

------

## Exhibit 99.1

![img164290822_0.jpg](img164290822_0.jpg)

------

![img164290822_1.jpg](img164290822_1.jpg)

------

![img164290822_2.jpg](img164290822_2.jpg)

------

## Exhibit 99.2

**Exhibit 99.2**

**FORM 51–102F3**

**MATERIAL CHANGE REPORT**

**Item 1. <u>Name and Address of Company</u>**

Liminal BioSciences Inc. ("**Liminal**" or the "**Company**")

440 Armand-Frappier Blvd., Suite 300

Laval, QC, H7V 4B4

**Item 2. <u>Date of Material Change</u>**

February 1, 2023.

**Item 3. <u>News Release</u>**

A press release describing the material change referred to in this report was disseminated by Liminal on January 26, 2023 on newswires in the United States and Canada and filed on SEDAR.

**Item 4. <u>Summary of Material Change</u>** 

On February 1, 2023, Liminal effected a consolidation of all of the issued and outstanding common shares of the Company ("**Common Shares**") on the basis of a consolidation ratio of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the "**Share Consolidation**").

**Item 5. <u>Full Description of Material Change</u>**

On February 1, 2023, Liminal effected a consolidation of all Common Shares on the basis of a consolidation ratio of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share. The Share Consolidation became effective at the opening of trading on February 1, 2023. The Company's trading symbol remains unchanged. The Share Consolidation was previously approved by the Company's shareholders at the special meeting of the shareholders held on January 20, 2023.

The Company has mailed a letter of transmittal ("**Letter of Transmittal**") to its registered holders of Common Shares which must be completed and returned to Computershare Investor Services Inc. ("**Computershare**") at the address specified in the Letter of Transmittal, together with their share certificates for the pre-consolidation Common Shares, in order to receive share certificates for the relevant number of post-consolidation Common Shares to which they are entitled to receive. Questions on how to complete the Letter of Transmittal, or requests for additional copies of the Letter of Transmittal, may be directed to Computershare at 1-800-564-6253 or by e-mail to corporateactions@computershare.com.

Shareholders that hold their Common Shares through a broker, trust company or other intermediary do not need to complete and submit a Letter of Transmittal, as their intermediary will make arrangements on their behalf for their accounts to be updated for the relevant number of post-consolidation Common Shares that they beneficially hold, as applicable.

**Item 6. <u>Reliance on Section 7.1(2) or (3) of National Instrument 51-102</u>**

Not applicable.

------

**Item 7. <u>Omitted Information</u>**

Not applicable.

**Item 8. <u>Executive Officer<br></u>**<br> The foregoing accurately discloses the material change referred to in this report and inquiries in respect of the material change referred to in this report may be made to:

Marie Iskra

General Counsel

m.iskra@liminalbiosciences.com

(450) 781-0115

**Item 9. <u>Date of Report<br></u>**<br> February 2, 2023

------